Therapeutic efficacy of Glargine Insulin combined with Acarbose in the treatment of patients with type 2 diabetes mellitus

Objective: To study therapeutic efficacy of Glargine Insulin combined with Acarbose in the treatment of type 2 diabetes mellitus(T2DM) and the efficacy of secretory function of pancreatic β-cell protection and improvement.Methods: 90 patients with T2DM were given Glargine Insulin and Acarbose after 16 weeks of treatment.The change of fasting plasma glucose(FPG),postprandial 2 h blood glucose(2 h PG),glycosylated hemoglobin(HbA1c),fasting C peptide(FCP),postprandial C peptide(PCP) were detected after 16 weeks of treatment.Results: After 16 weeks of treatment in patients with FPG,2 h PG,HbA1c decreased as the(6.91±1.50) mmol/L(t=1.669),(8.28±2.12) mmol/L(t=2.136),(6.51±1.03)%(t=1.663) descent,obviously after therapy,the differences were significant(P0.05).FCP,PCP were increased to(3.42±0.42) μg/L(t=2.178),(3.78±0.32) μg/L(t=2.752),both were higher than before treatment,there were significant differences(P0.05).Conclusion: The treatment of Glargine Insulin combined with Acarbose in T2DM has a good hypoglycemic effect and can improve the endocrine function of pancreatic β-cell.